Author Archives: admin


IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in … – Nature.com

Data collection

A comprehensive cancer genomics program, The Cancer Genome Atlas (TCGA) has conducted molecular characterizations of 33 primary cancer types. Using UALCAN (https://ualcan.path.uab.edu/analysis.html), exploration of FOXC1 expression in esophageal squamous cell carcinoma was conducted utilizing data extracted from the TCGA database.

Human esophageal squamous cell carcinoma cell lines, such as TE-1, ECA-109, KYSE-30, and KYSE-150, were procured from the Institute of Biological Sciences of the Chinese Academy of Sciences in Shanghai. Subsequently, routine mycoplasma contamination testing was conducted. Cells were maintained at 37C with 5% CO2, cultured in DMEM medium (GIBCO) containing 1% penicillin-streptomycin and 10% Fetal Bovine Serum (GIBCO).

Cells were seeded into 6-well plates for transient knockdown transfection, followed by the transfection of 100pmol siRNA-FOXC1 (GenePharma, Shanghai, China) using HighGene (ABclonal, Wuhan, China) ECAh well, following the manufacturers guidance. Cells were seeded into 6-well plates for transient gene overexpression transfection, followed by the transfection of the plasmids expressing CBX7 or IGF-1R were purchased from Genechem (Shanghai, China) using HighGene (ABclonal, Wuhan, China).

At 48h post-transfection, transfection efficiency was assessed using RT-qPCR and western blot. For stable transfection, ECA-109 and KYSE-150 cells were transfected with lentivirus vectors encoding either FOXC1-targeting shRNA or non-targeting control shRNA, following the manufacturers instructions (Genechem, Shanghai, China). Briefly, cells were seeded in 6-well plates, and when the cell density reached 30%, a medium containing viral fluid at an MOI of 10, without serum, was added. This medium was replaced with a complete medium 24h later. After lentiviral infection, ECA-109 cells and KYSE-150 cells underwent a two-week selection process with 1g/mL puromycin to obtain stable clones. Transfection efficiency for each vector was evaluated through a western blot.

In the cell migration experiment, 1 105 cells were re-suspended in 200L serum-free DMEM medium and added to the upper compartment, and 500 l DMEM medium containing 10%FBS was added to the lower compartment to induce the migration of cells. In the cell invasion experiment, the cells re-suspended in 200L serum-free DMEM medium were added to the upper chamber coated with Matrigel matrix (Corning, 356234), and the rest procedures were performed the same as the cell migration experiment. Fixation with 4% paraformaldehyde and staining with crystal violet dye were conducted after a 24-h incubation period. Subsequently, IMAGEJ software was employed for cell number quantification.

We introduced a seeding density of 2000 cells per well into 96-well plates and established an arrangement of 10 sub-wells. After the cells were fully attached to the plate, CCK8 reagent (10 l per well) was added at 0,24,48,72,96h, respectively. Subjected to incubation in the absence of light for an hour, the microplate reader was employed to analyze the absorbance at 450nM. Three repetitions of the experiments were executed, followed by the final statistical analysis performed using GraphPad Prism 8.0.

6-well plates were used for cell inoculation, with ECAh well receiving 1 103 cells, and subsequent culture was carried out in DMEM medium containing 10% FBS and 1% Penicillin-Streptomycin Solution. After a 14-day incubation period, cell fixation was performed using 4% paraformaldehyde, followed by staining with 0.1% crystal violet dye. The colony count was determined using ImageJ software.

The ECA-109 cells and KYSE-150 cells were plated into ultra-low six-well plates (Corning) at 1 103 cells/well. The cells were cultured in serum-free DMEM/F12(Gibco) with 2% B27(Invitrogen)20ng/mL EGF(PeproTech)20ng/mL bFGF(PeproTech) for 14 days. The size of the tumor spheroids was observed under a light microscope and the count of spheres with a diameter greater than 100M was counted.

ECA-109 cells and KYSE-150 cells were incubated in 6-well plates in DMEM supplemented with 10% FBS, 1% penicillin-streptomycin, and 1M cisplatin. After incubation for 24h, the cells were gathered, and an Annexin V-FITC apoptosis analysis kit (Elabscience Biotechnology) was utilized to assess the percentage of apoptotic cells, following the step-by-step instructions in the user manual. Results were represented as the mean of % cell death of at least three independent replicates.

1 106 ECA-109 cells and 1 106 KYSE-150 cells were incubated with CD44 antibody(R&D Systems)for 10min at room temperature, and washed twice twice after that. The FACS was performed using the Beckman CytoFLEX and the percentage of CD44+ cells was analyzed.

Cells were subjected to RNA isolation using Trizol (Vazyme) followed by reverse transcription into cDNA using the Reverse Transcriptase Kit (Abclonal). RT-qPCR was performed with the primers for FOXC1, CBX7, IGF- 1R, CD133, CD44, and -actin, and the fold change was calculated by the 2-Ct method. Cloud-Seq Biotech (Shanghai, China) conducted RNA high-throughput sequencing, wherein the removal of rRNAs was accomplished using the GenSeq rRNA Removal Kit (GenSeq, Inc.) with total RNA. After the removal of rRNA from the samples, library construction was carried out utilizing the GenSeq Low Input RNA Library Prep Kit (GenSeq, Inc.), following the prescribed protocol from the manufacturer. Quality control and quantification of the libraries were executed using the BioAnalyzer 2100 system (Agilent Technologies, Inc., USA). The sequencing of the libraries transpired on an Illumina Novaseq instrument, employing 150bp paired-end reads. Primer sequences are listed in Table 1.

Proteins were extracted using RIPA lysate (Beyotime) supplemented with 1% PMSF (Beyotime) and 2% phosphatase inhibitor (Beyotime). Following electrophoretic separation through SDS-PAGE, the proteins were transferred onto PVDF membranes. After blocking with 5% skim milk, primary antibodies specific for FOXC1 (ab227977, Abcam,1:1000), CD44 (A19020, Abclonal,1:1000), CD133 (A0219, Abclonal,1:1000), CBX7 (ab178411, Abcam,1:1000), IGF-1R (ab182408, Abcam,1:1000), phosphor-IGF-1R (ab39398, Abcam,1:1000), Akt (4691, Cell Signaling Technology,1:1000), phospho-Akt (S473) (4060, Cell Signaling Technology,1:1000), ERK1/2 (ab184699, Abcam,1:1000), phospho -ERK1/2 (ab201015, Abcam,1:1000) primary antibodies overnight and -actin (AC026, Abclonal,1:10000) as internal reference were used for protein examination. .

Cultivated cells were fixed, chromatin sonicated, immunoprecipitated, and DNA purified according to ChIP-IT High Sensitivity kit (Active Motif) instructions, and the relative abundance of target DNA was analyzed by qPCR. Primer sequences are listed in Table 1.

Tissue samples for this study were sourced from individuals diagnosed with esophageal squamous cell carcinoma at Tongji Universitys Dongfang Hospital, totaling 79 patients. Following fixation in formalin and embedding in paraffin, tissue sections were sliced to a thickness of 4m. Subsequently, the sections underwent deparaffinization and hydration through immersion in xylene and graded alcohols. Heat-induced antigen retrieval was conducted in EDTA buffer (pH 8.0) for 15minutes, utilizing a microwave oven. To minimize nonspecific staining, blocking was carried out with 10% goat serum. Following this, specific primary antibodies, including FOXC1 (ab227977, Abcam, 1:200), CD44 (A19020, Abclonal, 1:200), and CD133 (A0219, Abclonal, 1:100), were applied to the sections and left to incubate overnight at 4C. The slides were then counterstained with light hematoxylin, subjected to dehydration, and covered with slips. The outcomes were evaluated by two pathologists independently, with no access to clinical data, and subsequent analyses encompassed TNM staging and survival assessment. The study was conducted with the written informed consent of the patients and approved by the Institutional Review Committee of East Hospital Affiliated with Tongji University in Shanghai.

The Animal Protection and Use Committee of Tongji University approved all animal experiments. Animal experimentation involved the utilization of 10 BALB/c nude mice, all of the female gender and aged 6 weeks.KYSE-150-FOXC1-LV and KYSE-150-NC-LV were injected subcutaneously into the right abdomen of two groups of mice, purchased from Gempharmatech Co., Ltd. The mice were euthanized, and the tumors were subsequently extracted after 4 weeks for size measurement and weighing. A portion of the tumor tissue was fixed with 10% paraformaldehyde and paraffin-embedded for subsequent immunohistochemical staining analysis, and the rest was used for protein and mRNA extraction.

The in vivo experiments were repeated three times and the final results were taken as the meanstandard deviation. Statistical comparison analysis was performed by GraphPad Prism 8.0. For survival analysis, the Kaplan-Meier method and log-rank test were employed, and statistical significance was established for P values less than 0.05.

Go here to read the rest:
IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in ... - Nature.com

Stem Cells Explained: The Science Behind Osteoarthritis Treatments – Corporate Wellness Magazine

In recent years, stem cell therapy has emerged as a promising avenue for treating various medical conditions, including osteoarthritis. This innovative approach holds the potential to revolutionize the field of regenerative medicine, offering new hope for patients seeking alternatives to traditional treatments like surgery or medication. In this article, we delve into the science behind stem cell treatments for osteoarthritis, exploring how they work, their potential benefits, and considerations for those considering this option.

Stem cells are unique cells in the body with the remarkable ability to develop into different types of cells. They serve as the body's natural repair system, replenishing damaged tissues and organs. Stem cells can be found in various parts of the body, including bone marrow, adipose tissue (fat), and umbilical cord blood.

Osteoarthritis is a degenerative joint disease characterized by the breakdown of cartilage, the protective tissue that cushions the ends of bones in joints. This condition can lead to pain, stiffness, and reduced mobility. Traditional treatments focus on managing symptoms and may include pain medications, physical therapy, and in severe cases, joint replacement surgery.

Stem cell therapy offers a different approach by targeting the underlying cause of osteoarthritisthe deterioration of cartilage. By harnessing the regenerative potential of stem cells, researchers and clinicians aim to repair damaged cartilage and promote tissue regeneration within the joint.

In stem cell therapy for osteoarthritis, stem cells are harvested from the patient's own body or from other sources, such as umbilical cord tissue. These cells are then processed and concentrated before being injected directly into the affected joint.

Once injected, the stem cells work to reduce inflammation, stimulate tissue repair, and encourage the growth of new, healthy cartilage. This process is believed to slow down or even reverse the progression of osteoarthritis, providing long-term relief from pain and improving joint function.

One of the primary benefits of stem cell therapy for osteoarthritis is its potential to offer long-lasting pain relief and improved joint function without the need for surgery. Unlike traditional treatments that focus on symptom management, stem cell therapy addresses the underlying cause of the condition, offering the possibility of disease modification.

Additionally, stem cell therapy is minimally invasive and typically associated with minimal downtime and few complications. This makes it an attractive option for individuals looking to avoid the risks and lengthy recovery associated with surgical interventions.

While stem cell therapy holds promise for the treatment of osteoarthritis, it's essential for patients to approach this option with caution and realistic expectations. While research into the efficacy of stem cell therapy for osteoarthritis is ongoing, the evidence supporting its use is still evolving.

Patients considering stem cell therapy should consult with a qualified healthcare provider who can assess their condition, discuss treatment options, and provide guidance based on the latest scientific evidence. It's also important to thoroughly research any clinics or providers offering stem cell therapy and ensure they adhere to ethical and regulatory standards.

In conclusion, Stem cell therapy represents a promising frontier in the treatment of osteoarthritis, offering the potential for disease modification and long-term symptom relief. By harnessing the regenerative power of stem cells, researchers and clinicians are paving the way for innovative treatments that may transform the lives of millions affected by this debilitating condition. While more research is needed to fully understand the benefits and limitations of stem cell therapy for osteoarthritis, early results are promising, offering hope for a future where joint pain and disability are no longer inevitable consequences of aging and disease.

Given his unparalleled expertise and success in treating elite athletes and high-profile individuals, we highly recommend Dr. Chad Prodromos for anyone seeking top-tier stem cell treatment. His work at the Prodromos Stem Cell Institute is at the forefront of regenerative medicine, offering innovative solutions for a range of conditions. To explore how Dr. Prodromos can assist in your health journey, consider reaching out through his clinic's website for more detailed information and to schedule a consultation. visit Prodromos Stem Cell Institute.

Read more from the original source:
Stem Cells Explained: The Science Behind Osteoarthritis Treatments - Corporate Wellness Magazine

New sickle cell therapy uses gene editing at MUSC | Health | postandcourier.com – The Post and Courier

Sickle cell is widely misunderstood, even by many health care providers, so Peterson is making TikTok videos about it and about her journey to try and change that. Sickle cell patients in pain crises often run up against skeptical providers when they seek care because they look normal.

"Nothing shows on the outside," Peterson said.

Seemingly normal things can be difficult for them. For instance, flying can cause terrible pain for patients because of the air pressure or temperature change, butPeterson has still managed a few short hops with her younger brother Emmanuel, who is a pilot.

Olivia Peterson is no stranger to the pain crises. And even seemingly small things, like the weather, can trigger a crippling episode, said her mother, Vanessa, recalling a big 5th birthday party that had been planned. Then a storm front hit.

"We had to call and say, 'Were going to the hospital right now, so were sorry,' " Vanessa Peterson said. "She had her birthday in the hospital."

"Its not the first birthday I spent in the hospital," Olivia Peterson said, but she has learned to laugh about it now.

Vanessa Peterson (left) rests her chin on her daughter Olivia Peterson's shoulder while they sit on a hospital bed at MUSCs Sean Jenkins Childrens Hospital in Charleston on Feb. 8, 2024. Vanessa has been a huge supporter of her daughter over the years, driving her to appointments and sharing a laugh with her whenever possible. The two are very close.

There have been other disappointments along the way. MUSC and other centers have looked at bone marrow transplants for sickle cell patients as a potential long-term therapy, and that is when Jaroscak and Olivia Peterson met five years ago. But without a good donor match, she wasn't a candidate for that clinical trial.

Jaroscak continued with her other treatment, and when the RUBY trial came along and Peterson appeared to qualify, she picked up the phone.

"I called her up and said, 'Olivia, would you like to talk again?' " Jaroscak said.

For Peterson, it was like finding the Golden Ticket in the "Willy Wonka" movies, staring down at her chocolate bar in disbelief.

"I tell you it was one of those moments when you are so ready for something that you are not exactly really ready for it in that moment," she said. "Its right there, at your front door. And youre like, 'Oh, is this really happening right now?' "

See the original post:
New sickle cell therapy uses gene editing at MUSC | Health | postandcourier.com - The Post and Courier

Blood stem cell discovery could change future treatments – Local 5 – weareiowa.com

Geneticists found that receptors in cells, which activate immune response, also play a role in developing blood stem cells during embryonic development.

AMES, Iowa Iowa State University researchers recently made another scientific breakthrough in the genetics, development and cell biology department.

Led by Dr. Raquel Espin Palazon, researchers discovered that a protein known as "Nod1," which detects immune response, also plays a role in the development of blood stem cells during embryonic development.

The scientists used zebra fish to understand how blood stem cells are formed, because they have a similar developmental trajectory as humans.

Blood stem cells are produced only once, when we are embryos, and those cells migrate to our bone marrow where they are with us for life.

This discovery is important because it has the potential to have a significant impact on future stem cell treatments, Espin Palazon told Local 5 News.

The research could pave the way in assisting individuals with blood disorders like leukemia. With this new knowledge, scientists could eliminate the need for bone marrow transplants, which often come with complications.

"We are getting closer and closer to that big goal of you know, cure patients with their own cells," Espin Palazon said. "It just feels really good, yeah, we're really hoping, I think we could see that happening in our lifetimes."

Espin Palazon and other researchers have another paper under review after Nature Communications published this research.

Read more:
Blood stem cell discovery could change future treatments - Local 5 - weareiowa.com

Stem Cell Research: Latest Breakthroughs and Future Applications – Corporate Wellness Magazine

Stem cell research stands at the frontier of regenerative medicine, offering groundbreaking possibilities for the treatment of a myriad of diseases and injuries. This article explores the latest breakthroughs in stem cell research, shedding light on how these advancements are revolutionizing medical treatments and what the future may hold for this transformative field.

Stem cells are the body's raw materials from which all other cells with specialized functions are generated. Under certain physiological or experimental conditions, they can be induced to become tissue- or organ-specific cells with special functions. This ability makes stem cells incredibly valuable for medical research.

Recent years have witnessed significant advancements in stem cell research, leading to groundbreaking applications in the medical field. One of the most notable breakthroughs is the development of induced pluripotent stem cells (iPSCs). Scientists have discovered how to reprogram adult cells to an embryonic stem cell-like state, allowing them to generate any cell type within the body. This innovation opens up new avenues for understanding diseases, creating models for study, and developing and testing new drugs and therapies.

Another significant advancement is in the area of regenerative medicine. Researchers have successfully used stem cells to regenerate damaged tissues in organs such as the heart, liver, and kidneys. This is particularly promising for patients with conditions that are currently considered irreversible or incurable.

A wide range of stem cell-based therapies are currently undergoing clinical trials, targeting conditions such as Parkinson's disease, type 1 diabetes, spinal cord injuries, and various forms of cancer. These trials are critical for determining the safety and efficacy of stem cell therapies in treating these complex diseases.

The field of stem cell research is not without its ethical and regulatory challenges. The use of embryonic stem cells, in particular, has been a subject of ethical debate. However, the development of iPSCs has provided an alternative that may circumvent some of these ethical concerns. Regulatory bodies worldwide are working to establish frameworks that ensure the safe and ethical use of stem cell therapies.

Looking to the future, stem cell research holds the potential to revolutionize the field of medicine. One of the most anticipated applications is the ability to grow organs in the lab for transplantation, potentially solving the problem of organ shortage. Additionally, stem cells may play a crucial role in personalized medicine, where therapies are tailored to the individual based on their unique genetic makeup.

In conclusion, Stem cell research is rapidly evolving, with each breakthrough bringing us closer to understanding the full potential of stem cells in medicine. The future applications of stem cell research are vast and varied, offering hope for the treatment of diseases that are currently incurable. As the field continues to advance, it is poised to fundamentally alter the landscape of medical treatment, making what was once considered science fiction a reality.

Through continuous research and development, stem cell technology promises to unlock new therapies, improve the quality of life for patients with chronic conditions, and pave the way for innovative medical treatments. The journey of stem cell research is far from over; it is an exciting era of discovery and application that will undoubtedly shape the future of medicine.

Given his unparalleled expertise and success in treating elite athletes and high-profile individuals, we highly recommend Dr. Chad Prodromos for anyone seeking top-tier stem cell treatment. His work at the Prodromos Stem Cell Institute is at the forefront of regenerative medicine, offering innovative solutions for a range of conditions. To explore how Dr. Prodromos can assist in your health journey, consider reaching out through his clinic's website for more detailed information and to schedule a consultation. visit Prodromos Stem Cell Institute.

View original post here:
Stem Cell Research: Latest Breakthroughs and Future Applications - Corporate Wellness Magazine

Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine … – BioSpace

LOS ANGELES , Feb. 27, 2024 /PRNewswire/ -- Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, announced today that the company has closed a $16.75 million Series A financing led by GV with participation from Main Street Advisors, Visionary Ventures and YK BioVentures, to advance a first-in-class treatment for androgenetic alopecia or pattern baldness, and other types of alopecia including chemotherapy-induced hair loss.

"Our scientific co-founders have uncovered a unique biological mechanism with the potential to reactivate hair growth in people with alopecia," said Daniel Gil, Ph.D., Chief Executive Officer, Pelage Pharmaceuticals. "We are pleased to announce that we have completed a first-in-human Phase 1 clinical trial that demonstrated seven days of topical dosing with PP405 was safe and well-tolerated, and showed statistically significant activation of hair follicle stem cells. With the support of GV, Main Street Advisors and other top-tier investors, we expect to advance our lead program to a Phase 2a clinical trial in the second half of this year."

The Phase 1 trial evaluating PP405, a novel topical agent designed to treat androgenetic alopecia and other forms of hair loss, showed 0.05% PP405 topical treatment for seven days is safe and tolerable with no adverse events, and provided confirmation of a daily dosing regimen. Importantly, the study demonstrated biological activity, proof of mechanism of action seen in preclinical studies, and showed treatment with PP405 stimulated statistically significant activation of a critical hair follicle stem cell activation marker. Translational data will be presented at the American Academy of Dermatology meeting in March.

Androgenetic alopecia, also known as pattern balding, is the most common form of alopecia and accounts for more than 90% of all hair loss, impacting both men and women. Additionally, PP405 may also have applications for other types of hair loss such as telogen effluvium (stress-induced hair loss) and chemotherapy-induced hair loss.

"What we've observed is that in people who experience hair loss, the actual hair follicle stem cells are still present but have reverted to a dormant state. We have uncovered a small molecule able to stimulate cellular metabolism to re-awaken hair follicle stem cells and spur new hair growth," said William Lowry, Ph.D., scientific co-founder, Pelage Pharmaceuticals. The discovery was made by Drs. Lowry, Heather Christofk and Michael Jung, of the University of California, Los Angeles. PP405 is designed to inhibit the mitochondrial pyruvate carrier (MPC) to specifically reactivate the dormant hair follicle stem cells.

"Hair loss is an incredibly common health problem with few effective solutions," said Cathy Friedman, Executive Venture Partner, GV and Board Director, Pelage Pharmaceuticals. "GV is excited by the incredible science behind the Pelage technology. Pelage is pioneering an innovative approach with the potential to disrupt the treatment landscape, moving beyond agents that merely slow the progression of hair loss to a treatment solution that actually helps to regrow hair."

Along with the financing and Phase 1 topline data, Pelage has announced the appointment of Qing Yu Christina Weng, M.D., as the company's Chief Medical Officer (CMO). Dr. Weng is a physician-scientist, Harvard-trained board-certified dermatologist at Massachusetts General Hospital, and faculty at Harvard Medical School. In addition to her clinical expertise, Dr. Weng brings a background in corporate startup strategy and business development. At Pelage, Dr. Weng's experience will inform the company's development of PP405 as it advances to Phase 2 studies.

"The current therapeutic landscape is dominated by reformulations of existing products. Pelage is built on rigorous science and offers the opportunity to target the follicle stem cells directly," said Dr. Weng. "I am thrilled to work with the Pelage team to advance this discovery in pursuit of a novel non-invasive solution for all people who experience hair loss."

About Pelage Pharmaceuticals

Pelage Pharmaceuticals is a clinical-stage regenerative medicine company developing novel treatments for hair loss including androgenetic alopecia and chemotherapy-induced-alopecia. With a focus on molecular and stem cell biology, Pelage is advancing a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body's ability to naturally grow hair. Its lead program, PP405, is currently in clinical trials. Through its rigorous scientific foundation, topical formulation, and novel mechanism of action, Pelage is pioneering first-in-class hair growth solutions for people of all hair types experiencing hair loss.

About PP405

PP405 is a novel, non-invasive, topical small molecule designed to reactivate dormant hair follicle stem cells and restart hair growth. Through a regenerative medicine approach, the treatment focuses on addressing the metabolic processes that regulate the activation and inactivation phases of hair follicle stem cells. Early results from a Phase 1 trial show that PP405 was well-tolerated and demonstrated statistically significant activation of hair follicle stem cells. In 2018, Pelage Pharmaceuticals licensed the intellectual property to PP405 and related topical small molecules from the UCLA Technology Development Group.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pelage-pharmaceuticals-announces-16-75m-series-a-financing-led-by-gv-to-revolutionize-regenerative-medicine-for-hair-loss-302071733.html

SOURCE Pelage Pharmaceuticals

Read more:
Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - BioSpace

UC Irvine advances stem cell research with $4 million CIRM grant for shared resources lab – UCI News

Irvine, Calif., Feb. 26, 2024 The University of California, Irvine has received a five-year, $4 million grant from the California Institute for Regenerative Medicine to establish a shared resources lab in the Sue & Bill Gross Stem Cell Research Center. The facility will offer essential technologies and training for the development of novel in vitro stem cell-based modeling that will serve researchers across the campus and the state.

Stem cells possess the potential to transform into particular cell types, offering promising avenues for rejuvenating and restoring tissues harmed by injury or affected by disease, said principal investigator Craig Walsh, UCI professor of molecular biology and biochemistry. Utilizing stem cell modeling facilitates the development of new treatments and drug screening platforms and also provides deeper understanding of both discovery and translational research processes.

The grant will expand the UCI stem cell centers current lab capabilities, including the addition of new and upgraded equipment, instrumentation and components, and establish new services and user training in four key areas: foundational technologies, bioengineering and organoids, gene editing, and high-dimensional spatial analysis. Training is essential to characterize stem cell models, develop novel regenerative medicine therapeutics, and ensure that theres a workforce capable of implementing new strategies.

Our state-of-the-art facility and cutting-edge training opportunities demonstrate our commitment to advancing stem cell research and discovery, as well as to education and skill enhancement, said Aileen Anderson, Ph.D., director of the UCI stem cell center and professor of physical medicine & rehabilitation at the UCI School of Medicine.

The impact of the labs initiatives will foster collaborations with academic and industrial partners throughout California and leverage existing training programs such as CIRM Bridges to accelerate innovation. This effort underscores the scientific communitys drive to transform the landscape of regenerative medicine.

The Sue & Bill Gross Stem Cell Research Centers shared resources lab will contribute to the broader CIRM mission to develop a stem cell-based modeling ecosystem throughout California, supporting the basic and translational research necessary to advance scientific discoveries and the development of new therapeutic solutions for unmet medical needs, ranging from neurological diseases to cancer.

About UCIs Brilliant Future campaign:Publicly launched on Oct. 4, 2019, the Brilliant Future campaign aims to raise awareness and support for UCI. By engaging 75,000 alumni and garnering $2 billion in philanthropic investment, UCI seeks to reach new heights of excellence instudent success, health and wellness, research and more. The School of Biological Sciences plays a vital role in the success of the campaign. Learn more by visitinghttps://brilliantfuture.uci.edu/school-of-biological-sciences.

About the University of California, Irvine:Founded in 1965, UCI is a member of the prestigious Association of American Universities and is ranked among the nations top 10 public universities byU.S. News & World Report. The campus has produced five Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 36,000 students and offers 224 degree programs. Its located in one of the worlds safest and most economically vibrant communities and is Orange Countys second-largest employer, contributing $7 billion annually to the local economy and $8 billion statewide.For more on UCI, visitwww.uci.edu.

Media access: Radio programs/stations may, for a fee, use an on-campus ISDN line to interview UCI faculty and experts, subject to availability and university approval. For more UCI news, visit news.uci.edu. Additional resources for journalists may be found at communications.uci.edu/for-journalists.

Continue reading here:
UC Irvine advances stem cell research with $4 million CIRM grant for shared resources lab - UCI News

Top Stem Cell Clinics in the World: Pioneering Future Medicine – Corporate Wellness Magazine

The realm of regenerative medicine, particularly stem cell therapy, has witnessed exponential growth over the past few decades. Stem cells offer the remarkable potential to repair, regenerate, and rejuvenate tissues and organs, presenting new horizons in treating various diseases and injuries. This article delves into the pioneering world of stem cell clinics, showcasing institutions leading the charge in harnessing the transformative power of stem cell therapies. These clinics are not just medical facilities; they are the epicenters of innovation and research that are reshaping the future of medicine.

Stem cell clinics across the globe are pushing the boundaries of medical science. They specialize in harvesting, manipulating, and deploying stem cells to treat a myriad of conditions, from chronic diseases to orthopedic injuries and beyond. These institutions are characterized by their state-of-the-art facilities, interdisciplinary teams of experts, and a commitment to research and development.

The top stem cell clinics are renowned for their pioneering work in developing and applying cutting-edge treatments. They utilize a variety of stem cells, including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult stem cells, each serving different therapeutic purposes. Treatments range from repairing damaged cartilage in joints, treating autoimmune diseases, to pioneering efforts in neurodegenerative diseases like Parkinsons and Alzheimers.

Research is a cornerstone of these leading clinics. They are often affiliated with academic institutions and participate in global research initiatives, contributing to the growing body of scientific literature on stem cell therapies. These clinics are at the forefront of translating laboratory discoveries into clinical applications, ensuring that treatments are both safe and effective.

The global nature of top stem cell clinics reflects the universal demand for advanced medical treatments. Many of these clinics have become hubs for medical tourism, attracting patients worldwide seeking access to the latest in regenerative medicine. This international aspect underscores the importance of regulatory standards and ethical considerations in stem cell therapy, areas in which these clinics lead by example.

Adhering to stringent ethical and regulatory standards is paramount. The best stem cell clinics operate with transparency, obtaining proper consents, and following rigorous protocols to ensure patient safety and treatment efficacy. They navigate the complex landscape of stem cell research and therapy with integrity, contributing to the field's ethical advancement.

What sets these clinics apart is their holistic, patient-centric approach. Understanding that each patient's needs and conditions are unique, they offer personalized treatment plans. This bespoke approach ensures that patients receive the most appropriate stem cell therapy, maximizing the potential for successful outcomes.

As the field of regenerative medicine continues to evolve, so too will the role of stem cell clinics. With ongoing research and technological advancements, the potential applications of stem cell therapy will expand, offering hope for incurable and untreatable conditions. These clinics are not just treating patients; they are shaping the future of healthcare.

In conclusion, The top stem cell clinics in the world are more than medical facilities; they are beacons of hope for patients and catalysts for change in the medical community. Their pioneering work in regenerative medicine exemplifies the power of stem cell therapy to transform lives. As they continue to innovate and lead, the promise of future medicine becomes increasingly tangible, marking a new era in healthcare where regeneration and healing are at the forefront.

Given his unparalleled expertise and success in treating elite athletes and high-profile individuals, we highly recommend Dr. Chad Prodromos for anyone seeking top-tier stem cell treatment. His work at the Prodromos Stem Cell Institute is at the forefront of regenerative medicine, offering innovative solutions for a range of conditions. To explore how Dr. Prodromos can assist in your health journey, consider reaching out through his clinic's website for more detailed information and to schedule a consultation. visit Prodromos Stem Cell Institute.

Here is the original post:
Top Stem Cell Clinics in the World: Pioneering Future Medicine - Corporate Wellness Magazine

The Promise and Reality of Stem Cell Therapy: What You Need to Know – Corporate Wellness Magazine

In the rapidly evolving world of medicine, stem cell therapy emerges as a beacon of hope for individuals suffering from a range of chronic diseases, injuries, and conditions previously thought untreatable through conventional methods. As the medical community continues to unlock the potential of stem cells, patients and healthcare professionals alike are keenly interested in understanding the promises and realities of this innovative treatment option. This article delves into the intricacies of stem cell therapy, offering a comprehensive overview of what patients need to know.

Stem cell therapy, a cornerstone of regenerative medicine, utilizes stem cells to repair or replace damaged cells, tissues, or organs. This approach has the potential to treat a variety of conditions, including but not limited to, degenerative diseases, spinal cord injuries, and heart disease. The promise of stem cell therapy lies in its ability to promote healing and regenerate damaged tissues, offering hope for long-term recovery and a significant improvement in quality of life.

Stem cells can be classified into two main categories: autologous and allogeneic. Autologous stem cells are derived from the patient's own body, minimizing the risk of immune rejection. Allogeneic stem cells, on the other hand, are sourced from a donor. Each type has its applications and considerations, including ethical concerns, availability, and potential for immune response.

The allure of stem cell therapy lies in its versatility and the potential for groundbreaking treatment outcomes. It offers prospects for regenerating damaged heart tissue, treating neurodegenerative diseases like Parkinson's and Alzheimer's, and repairing bones and cartilage in conditions such as osteoarthritis. Moreover, ongoing research continues to explore its efficacy in treating autoimmune diseases, diabetes, and other chronic conditions.

While the potential of stem cell therapy is vast, it's essential for patients and healthcare providers to navigate its realities with a clear understanding. The field is still in its experimental stages for many applications, meaning that treatments may not always lead to successful outcomes. There are also risks associated with stem cell therapy, including infection, immune rejection, and the possibility of the cells differentiating into unintended tissue types.

The ethical and legal landscape surrounding stem cell therapy is complex, involving debates over the use of embryonic stem cells, consent, and the potential for misuse. Legislation varies by country, impacting the availability and regulatory oversight of stem cell treatments. Patients considering treatment abroad should be well-informed about the legal and ethical frameworks governing stem cell therapy in their chosen destination.

As stem cell therapy becomes more sought-after, medical tourism plays a significant role in connecting patients with treatment options worldwide. It's crucial for those considering treatment abroad to conduct thorough research, ensuring the chosen facility adheres to international standards, employs qualified professionals, and operates with transparency regarding treatment outcomes and potential risks.

For patients exploring stem cell therapy, setting realistic expectations is paramount. Success rates can vary widely depending on the condition being treated, the type of stem cells used, and the patient's overall health. It's important to engage in detailed discussions with healthcare providers to understand the potential benefits and limitations of the treatment.

In conclusion, Stem cell therapy represents a frontier in modern medicine, offering promising solutions for conditions once deemed incurable. However, it's accompanied by a spectrum of ethical, legal, and practical considerations that patients must navigate. By staying informed and consulting with medical professionals, individuals can make educated decisions about pursuing stem cell therapy, fully aware of its promises and realities. As the field continues to evolve, the hope is that advancements in research and regulatory frameworks will further unlock the potential of stem cells, making safe and effective treatments more accessible to those in need.

Given his unparalleled expertise and success in treating elite athletes and high-profile individuals, we highly recommend Dr. Chad Prodromos for anyone seeking top-tier stem cell treatment. His work at the Prodromos Stem Cell Institute is at the forefront of regenerative medicine, offering innovative solutions for a range of conditions. To explore how Dr. Prodromos can assist in your health journey, consider reaching out through his clinic's website for more detailed information and to schedule a consultation. visit Prodromos Stem Cell Institute.

Read this article:
The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine

Treating Diabetes with Stem Cells: Exploring the Possibilities – Corporate Wellness Magazine

The prevalence of diabetes globally underscores an urgent need for more effective and innovative treatment methodologies. Traditional diabetes management strategies have centered around insulin therapy, lifestyle modifications, and various medications to control blood sugar levels. However, these approaches often require lifelong adherence and management, without offering a cure. Enter the realm of regenerative medicine, specifically stem cell therapy, which presents a promising frontier in the quest for not just managing but potentially treating diabetes. This article explores the potential of stem cells in revolutionizing diabetes treatment, offering insights into the science, the current state of research, the benefits, and the challenges that lie ahead.

Stem cell therapy involves using stem cells to regenerate or repair diseased tissues and organs. For diabetes, this means focusing on the pancreas, where insulin-producing beta cells are damaged or insufficient. The theory is that stem cells can either be directed to become insulin-producing cells or support the regeneration of the patient's own beta cells, thus restoring the body's ability to regulate blood sugar levels naturally.

There are primarily two types of diabetes: Type 1, an autoimmune condition where the immune system attacks the pancreas' beta cells, and Type 2, characterized by insulin resistance and beta-cell dysfunction. Stem cell therapy aims to address the root causes of both types by either replacing the lost beta cells or by modulating the immune system to stop the attack on these cells.

Research into stem cell therapy for diabetes is at a pivotal stage, with numerous clinical trials underway to evaluate the safety and efficacy of various stem cell-based treatments. These studies range from using embryonic stem cells, which have the potential to become any cell type, to induced pluripotent stem cells (iPSCs), adult stem cells reprogrammed to an embryonic-like state. Another area of research focuses on mesenchymal stem cells (MSCs), which can modulate the immune system and reduce inflammation, potentially halting the autoimmune attack on beta cells in Type 1 diabetes.

The potential benefits of stem cell therapy for diabetes are substantial. For individuals with Type 1 diabetes, it offers the hope of reducing or eliminating the need for insulin therapy by restoring natural insulin production. For those with Type 2 diabetes, stem cell therapy could improve insulin sensitivity and beta-cell function, addressing the disease's underlying causes rather than just its symptoms. Beyond glycemic control, stem cell therapy may also reduce the risk of diabetes-related complications, such as cardiovascular disease, neuropathy, and kidney damage, by providing a more comprehensive and lasting solution.

Despite its promise, stem cell therapy for diabetes faces several challenges. The complexity of accurately directing stem cells to become functional, insulin-producing beta cells in the right quantities, and ensuring their long-term survival and integration, remains a significant hurdle. Additionally, there are ethical and regulatory considerations surrounding stem cell research, particularly with embryonic stem cells. The cost and accessibility of stem cell therapies, once approved and available, are also critical factors that will determine their impact on diabetes care.

As stem cell therapy for diabetes progresses, medical tourism emerges as a vital avenue for patients seeking access to cutting-edge treatments not yet available in their home countries. Countries leading in regenerative medicine research offer specialized clinics providing experimental or newly approved stem cell therapies, attracting patients worldwide. However, it's essential for patients considering medical tourism for stem cell therapy to conduct thorough research, understand the risks and benefits, and choose reputable clinics and medical practitioners.

The ongoing advancements in stem cell research and therapy hold the promise of transforming diabetes treatment. From potentially offering a cure for Type 1 diabetes to significantly improving management options for Type 2 diabetes, the implications are profound. As research continues and therapies advance through clinical trials, the hope is that stem cell therapy will become a safe, effective, and widely accessible treatment option for diabetes patients worldwide.

In conclusion, treating diabetes with stem cells represents a frontier in medical science that could redefine the management of this chronic condition. With each research breakthrough, we move closer to a future where diabetes could be managed more effectively or possibly cured, offering new hope to millions affected by this disease. As we explore the possibilities of stem cell therapy, the potential to change lives and reshape the future of diabetes care is immense, marking a significant milestone in medical innovation and patient care.

Given his unparalleled expertise and success in treating elite athletes and high-profile individuals, we highly recommend Dr. Chad Prodromos for anyone seeking top-tier stem cell treatment. His work at the Prodromos Stem Cell Institute is at the forefront of regenerative medicine, offering innovative solutions for a range of conditions. To explore how Dr. Prodromos can assist in your health journey, consider reaching out through his clinic's website for more detailed information and to schedule a consultation. visit Prodromos Stem Cell Institute

More:
Treating Diabetes with Stem Cells: Exploring the Possibilities - Corporate Wellness Magazine